Clinical Trial Update: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC [Phase 2]

View source ↗

Summary

Phase 2 trial assessing OSE2101 alone or in combination with pembrolizumab versus best supportive care in patients with platinum-sensitive or relapsed ovarian c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• OSE2101
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING